Skip to main content

Zymeworks Inc.

ZYME
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001937653

No open-market purchases or sales by Zymeworks Inc. insiders were filed in the last 90 days; 202 institutions reported holding it in 13F filings for Q2 2026, worth $1.82B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Zymeworks Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Zymeworks Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Zymeworks Inc.
NameTitleLast reported holdingLast filingFilings, past year
Hollywood MarkEVP & Chief Operating Officer133,852Jul 6, 20262
Schneider Paul REVP, General Counsel–May 15, 20261
Platshon ScottEVP, Chief Business Officer–Apr 10, 20261
Schayowitz AdamSee Remarks–Apr 10, 20261
Stafford KristinEVP, Chief Financial Officer–Apr 7, 20261
Cherry Brian NDirector–Jan 13, 20261
Mahony SusanDirector–Jan 12, 20261
Neu KelvinDirector–Jan 12, 20261
Galbraith KennethChair & CEO226,842Jan 12, 20263
Landry Robert EDirector–Jan 12, 20261
Smith Jeffrey T LEVP & Chief Medical Officer26,708Jan 12, 20262
Campoy CarlosDirector–Jan 12, 20261
Cesano AlessandraDirector–Jan 12, 20261
Moore Paul AndrewChief Scientific Officer48,497Jan 12, 20262
Ciongoli Gregory AustinDirector488,500Jan 12, 20261
Patterson Leone DEVP, Chief Bus & Fin Officer459Jan 7, 20261
Nodelman OlegDirector, 10% Owner22,970,388IndirectJun 27, 20250
EcoR1 Capital, LLCDirector, 10% Owner22,970,388IndirectJun 27, 20250
Cox TroyDirector–Dec 12, 20240
Miller Derek John MichaelDirector–Dec 12, 20240
Gallagher NeilDirector–Dec 12, 20240
Davidson NancyDirector–Dec 12, 20240
Astle ChristopherSVP & Chief Financial Officer6,503Jan 8, 20240
Renton HollingsDirector–Dec 8, 20230
Hillan Kenneth J.Director–Dec 8, 20230
Klompas Neil APresident & COO17,032Mar 14, 20230
Zoth Lota S.Director–Dec 23, 20220
Sacks NatalieDirector–Dec 23, 20220
Josephson NeilChief Medical Officer14,449Dec 23, 20220
Redmile Group, LLC10% Owner6,075,918IndirectOct 18, 20220
Green Jeremy10% Owner6,075,918IndirectOct 18, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jan 13, 2026 (view filing)Jan 121 dayHollywood MarkEVP & Chief Operating OfficerSSale−6.12K$22.67−$138.7K−4.4%132.9K after
Jan 12, 2026 (view filing)Jan 12Same daySmith Jeffrey T LEVP & Chief Medical OfficerSSale−9.31K$22.67−$211.1K−25.8%26.7K after
Jan 12, 2026 (view filing)Jan 12Same dayMoore Paul AndrewChief Scientific OfficerSSale−9.56K$22.67−$216.7K−16.5%48.5K after
Jan 12, 2026 (view filing)Jan 12Same dayGalbraith KennethChair & CEOSSale−30.4K$22.67−$689.7K−11.8%226.8K after
Jan 5, 2026 (view filing)Jan 5Same daySmith Jeffrey T LEVP & Chief Medical OfficerSSale−10.5K$25.10−$264.5K−36.5%18.4K after
Jan 5, 2026 (view filing)Jan 5Same dayGalbraith KennethChair & CEOSSale−54.3K$25.10−$1.36M−21.9%193.3K after2 lots
Jan 5, 2026 (view filing)Jan 5Same dayMoore Paul AndrewChief Scientific OfficerSSale−20.1K$25.10−$504.8K−33.2%40.4K after2 lots
Dec 22, 2025 (view filing)Dec 22Same dayGalbraith KennethChair & CEOSSale−47.5K$27.02−$1.28M−26.3%133.3K after
May 19, 2025 (view filing)6:35 PM ETMay 15-194 daysNodelman Oleg and 1 otherDirector, 10% OwnerPPurchase+55.4K$11.47+$635.6K+0.3%17.9M after2 lots
Apr 18, 2025 (view filing)3:17 PM ETApr 16-172 daysNodelman Oleg and 1 otherDirector, 10% OwnerPPurchase+128.7K$11.32+$1.46M+0.7%17.8M after2 lots
Apr 7, 2025 (view filing)6:34 PM ETApr 3-44 daysNodelman Oleg and 1 otherDirector, 10% OwnerPPurchase+317.2K$11.42+$3.62M+1.8%17.7M after2 lots
Apr 2, 2025 (view filing)7:02 PM ETMar 31-Apr 22 daysNodelman Oleg and 1 otherDirector, 10% OwnerPPurchase+127.4K$11.75+$1.50M+0.7%17.4M after3 lots
Mar 27, 2025 (view filing)6:53 PM ETMar 25-262 daysNodelman Oleg and 1 otherDirector, 10% OwnerPPurchase+97.3K$12.61+$1.23M+0.6%17.3M after2 lots
Mar 24, 2025 (view filing)5:45 PM ETMar 20-244 daysNodelman Oleg and 1 otherDirector, 10% OwnerPPurchase+127.2K$12.92+$1.64M+0.7%17.2M after3 lots
Mar 19, 2025 (view filing)6:32 PM ETMar 17-192 daysNodelman Oleg and 1 otherDirector, 10% OwnerPPurchase+228.5K$12.55+$2.87M+1.4%17.0M after3 lots
Mar 13, 2025 (view filing)7:35 PM ETMar 11-132 daysNodelman Oleg and 1 otherDirector, 10% OwnerPPurchase+1.08M$12.13+$13.1M+6.9%16.8M after3 lots
Jan 21, 2025 (view filing)Jan 16-175 daysEcoR1 Capital, LLCDirector, 10% OwnerPPurchase+141.4K$13.89+$1.96M+0.9%15.7M after2 lots
Jan 15, 2025 (view filing)Jan 13-152 daysEcoR1 Capital, LLCDirector, 10% OwnerPPurchase+167.7K$13.59+$2.28M+1.1%15.6M after3 lots
Jan 10, 2025 (view filing)Jan 8-102 daysEcoR1 Capital, LLCDirector, 10% OwnerPPurchase+225.1K$13.22+$2.98M+1.5%15.4M after2 lots
Jan 6, 2025 (view filing)Jan 6Same dayMoore Paul AndrewChief Scientific OfficerSSale−21.2K$14.92−$316.3K−47.6%23.3K after2 lots
Jan 6, 2025 (view filing)Jan 6Same dayGalbraith KennethChair & CEOSSale−57.3K$14.92−$854.8K−41.5%80.8K after2 lots
Jan 6, 2025 (view filing)Jan 6Same daySmith Jeffrey T LEVP & Chief Medical OfficerSSale−11.1K$14.92−$165.8K−55.6%8.89K after
Jan 2, 2025 (view filing)Dec 30, 2024-Jan 2, 20253 daysEcoR1 Capital, LLCDirector, 10% OwnerPPurchase+363.4K$14.65+$5.32M+2.5%15.2M after3 lots
Dec 27, 2024 (view filing)Dec 24-273 daysEcoR1 Capital, LLCDirector, 10% OwnerPPurchase+130.3K$14.44+$1.88M+0.9%14.8M after3 lots
Dec 26, 2024 (view filing)Dec 19-237 daysEcoR1 Capital, LLCDirector, 10% OwnerPPurchase+1.25M$13.98+$17.5M+9.3%14.7M afterAmended3 lots
Jan 8, 2024 (view filing)Jan 5-83 daysGalbraith KennethChair & CEOSSale−23.9K$10.79−$257.8K−50.1%23.8K after2 lots
Jan 8, 2024 (view filing)Jan 5-83 daysAstle ChristopherSVP & Chief Financial OfficerSSale−5.99K$10.79−$64.7K−48.0%6.50K after2 lots
Jan 8, 2024 (view filing)Jan 5-83 daysMoore Paul AndrewChief Scientific OfficerSSale−9.80K$10.79−$105.7K−57.1%7.37K after2 lots
Dec 28, 2023 (view filing)Dec 262 daysEcoR1 Capital, LLC10% OwnerPPurchase+5.09M$9.83+$50.0M–5.09M afterDerivative
Dec 11, 2023 (view filing)Dec 11Same dayAstle ChristopherSVP & Chief Financial OfficerSSale−886$9.13−$8.09K−30.7%2.00K after
Jun 21, 2023 (view filing)Jun 165 daysEcoR1 Capital, LLC10% OwnerPPurchase+3.35M$8.12+$27.2M+33.2%13.4M after
Mar 30, 2023 (view filing)Mar 282 daysEcoR1 Capital, LLC10% OwnerPPurchase+200.0K$8.00+$1.60M+2.0%10.1M after
Mar 14, 2023 (view filing)Mar 104 daysKlompas Neil APresident & COOSSale−2.98K$7.83−$23.3K−14.9%17.0K after
Jan 23, 2023 (view filing)Jan 19-204 daysEcoR1 Capital, LLC10% OwnerPPurchase+307.5K$9.70+$2.98M+3.2%9.89M after2 lots
Jan 18, 2023 (view filing)Jan 13-185 daysEcoR1 Capital, LLC10% OwnerPPurchase+985.1K$9.84+$9.70M+11.5%9.58M after3 lots
Jan 12, 2023 (view filing)Jan 10-112 daysEcoR1 Capital, LLC10% OwnerPPurchase+1.03M$7.67+$7.87M+13.6%8.59M after2 lots
Dec 23, 2022 (view filing)Dec 1211 daysAstle ChristopherSVP & Chief Financial OfficerSSale−887$6.01−$5.33K−40.0%1.33K afterAmended
Dec 23, 2022 (view filing)Nov 1043 daysJosephson NeilChief Medical OfficerSSale−2.48K$8.10−$20.0K−14.6%14.4K afterAmended
Oct 18, 2022 (view filing)6:07 AM ETOct 135 daysRedmile Group, LLC and 1 other10% OwnerPPurchaseCommon Stock, par value $0.00001 per share+30.5K$5.03+$153.4K+0.5%6.08M afterAmended